123 related articles for article (PubMed ID: 35235173)
1. In Vitro and In-Eye Comparison of Commercial Pilocarpine Ophthalmic Solution and an Optimized, Reformulated Pilocarpine for Presbyopia Treatment.
Jackson MA; Giyanani J; Shabaik Y; Penzner J; Gore AV; Robinson MR; Waring GO
Ophthalmol Ther; 2022 Apr; 11(2):869-879. PubMed ID: 35235173
[TBL] [Abstract][Full Text] [Related]
2. Combinations of Pilocarpine and Oxymetazoline for the Pharmacological Treatment of Presbyopia: Two Randomized Phase 2 Studies.
Price FW; Hom M; Moshirfar M; Evans D; Liu H; Penzner J; Robinson MR; Lee S; Wirta DL
Ophthalmol Sci; 2021 Dec; 1(4):100065. PubMed ID: 36246939
[TBL] [Abstract][Full Text] [Related]
3. Impact of presbyopia treatment pilocarpine hydrochloride 1.25% on night-driving performance.
Waring GO; Brujic M; McGee S; Micheletti JM; Zhao C; Schachter S; Liu H; Safyan E
Clin Exp Optom; 2023 Dec; ():1-8. PubMed ID: 38044272
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of AGN-190584 in Individuals With Presbyopia: The GEMINI 1 Phase 3 Randomized Clinical Trial.
Waring GO; Price FW; Wirta D; McCabe C; Moshirfar M; Guo Q; Gore A; Liu H; Safyan E; Robinson MR
JAMA Ophthalmol; 2022 Apr; 140(4):363-371. PubMed ID: 35238902
[TBL] [Abstract][Full Text] [Related]
5. Understanding Perspectives on Presbyopia and Use of Pilocarpine HCl 1.25% Twice Daily from Participants of the Phase 3 VIRGO Study.
Shafer BM; McGee SR; Ifantides C; Williamson BK; Kannarr S; Whyte J; Zhang Z; Yanke T; Schachter S
Ophthalmol Ther; 2024 Jun; 13(6):1723-1742. PubMed ID: 38662193
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Twice-Daily Pilocarpine HCl in Presbyopia: The Virgo Phase 3, Randomized, Double-Masked, Controlled Study.
Kannarr S; El-Harazi SM; Moshirfar M; Lievens C; Kim JL; Peace JH; Safyan E; Liu H; Zheng S; Robinson MR
Am J Ophthalmol; 2023 Sep; 253():189-200. PubMed ID: 37149245
[TBL] [Abstract][Full Text] [Related]
7. Topical Review: Pilocarpine-induced Miosis as Help for Early Presbyopes?
Westheimer G
Optom Vis Sci; 2022 Aug; 99(8):632-634. PubMed ID: 35848990
[TBL] [Abstract][Full Text] [Related]
8. Pilocarpine 1.25% and the changing landscape of presbyopia treatment.
Meghpara BB; Lee JK; Rapuano CJ; Mian SI; Ho AC
Curr Opin Ophthalmol; 2022 Jul; 33(4):269-274. PubMed ID: 35779051
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model.
Berdy GJ; Spangler DL; Bensch G; Berdy SS; Brusatti RC
Clin Ther; 2000 Jul; 22(7):826-33. PubMed ID: 10945509
[TBL] [Abstract][Full Text] [Related]
10. Vuity - pilocarpine ophthalmic solution for presbyopia.
Med Lett Drugs Ther; 2022 Feb; 64(1643):17-18. PubMed ID: 35134046
[No Abstract] [Full Text] [Related]
11. Short-term tolerability of once-daily timolol hemihydrate 0.5%, timolol maleate in sorbate 0.5%, and generic timolol maleate gel-forming solution 0.5% in glaucoma and/or ocular hypertension: a prospective, randomized, double-masked, active-controlled, three-period crossover pilot study.
Sonty S; Mundorf TK; Stewart JA; Stewart WC
Clin Ther; 2009 Oct; 31(10):2063-71. PubMed ID: 19922877
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease.
Nichols KK; Donnenfeld ED; Karpecki PM; Hovanesian JA; Raychaudhuri A; Shojaei A; Zhang S
Eur J Ophthalmol; 2019 Jul; 29(4):394-401. PubMed ID: 30112930
[TBL] [Abstract][Full Text] [Related]
13. Effect of topically applied pilocarpine on tear film pH.
Longwell A; Birss S; Keller N; Moore D
J Pharm Sci; 1976 Nov; 65(11):1654-7. PubMed ID: 11334
[TBL] [Abstract][Full Text] [Related]
14. Retinal Detachments Associated With Topical Pilocarpine Use for Presbyopia.
Al-Khersan H; Flynn HW; Townsend JH
Am J Ophthalmol; 2022 Oct; 242():52-55. PubMed ID: 35609677
[TBL] [Abstract][Full Text] [Related]
15. Temporal Effects of 2% Pilocarpine Ophthalmic Solution on Human Pupil Size and Accommodation.
Kinney M; Johnson AD; Reddix M; McCann MB
Mil Med; 2020 Jan; 185(Suppl 1):435-442. PubMed ID: 32074356
[TBL] [Abstract][Full Text] [Related]
16. A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease.
Wirta DL; Torkildsen GL; Moreira HR; Lonsdale JD; Ciolino JB; Jentsch G; Beckert M; Ousler GW; Steven P; Krösser S
Ophthalmology; 2019 Jun; 126(6):792-800. PubMed ID: 30703441
[TBL] [Abstract][Full Text] [Related]
17. A Randomized Trial of Topical Fibrinogen-Depleted Human Platelet Lysate Treatment of Dry Eye Secondary to Chronic Graft-versus-Host Disease.
Sugar A; Hussain M; Chamberlain W; Dana R; Kelly DP; Ta C; Irvine J; Daluvoy M; Perez V; Olson J; Jhanji V; Walts TA; Stulting RD; Waller EK; Jagirdar N;
Ophthalmol Sci; 2022 Sep; 2(3):100176. PubMed ID: 36245754
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children.
Silverstein BE; Allaire C; Bateman KM; Gearinger LS; Morris TW; Comstock TL
Clin Ther; 2011 Jan; 33(1):13-26. PubMed ID: 21397770
[TBL] [Abstract][Full Text] [Related]
19. Effect of a hyaluronic acid and carboxymethylcellulose ophthalmic solution on ocular comfort and tear-film instability after cataract surgery.
Mencucci R; Boccalini C; Caputo R; Favuzza E
J Cataract Refract Surg; 2015 Aug; 41(8):1699-704. PubMed ID: 26432128
[TBL] [Abstract][Full Text] [Related]
20. Pilocarpine incorporated into a submicron emulsion vehicle causes an unexpectedly prolonged ocular hypotensive effect in rabbits.
Naveh N; Muchtar S; Benita S
J Ocul Pharmacol; 1994; 10(3):509-20. PubMed ID: 7836859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
